In particular, the immune response was heterogeneous among various KRAS-mutant colon cancers; KRAS-mutant CSM2 samples had the lowest Th1-centric coordinate immune response cluster, reduced expression of the IFN-γ pathway, signal transducer and activator of transcription 1 (STAT1) and motif chemokine 10 (CXCL10), and reduced infiltration of T lymphocytes and neutrophils, compared to CMS1 and CMS4 and to KRAS-WT CMS2 [254]. This evidence concerns the gene KRAS and colonic neoplasm.